Quoin Pharmaceuticals, Ltd. 8K

Quoin Pharmaceuticals’ 8-K announces major regulatory milestones and clinical development progress for QRX003 and QRX009 alongside first quarter 2026 financial results, with sufficient cash projected to fund operations into 2027.

Quoin Pharmaceuticals Ltd. reported its first quarter 2026 financial results and provided a comprehensive corporate and regulatory update, highlighting significant progress for its lead product candidate QRX003 for Netherton Syndrome, including Fast Track Designation from the U.S. FDA, confirmation from Japan’s MHLW that QRX003 qualifies for both Orphan Drug Designation and Fast Track review, and a Breakthrough Medicine Designation application filed with the Saudi FDA. The company disclosed that the FDA indicated a single Phase 3 study, potentially without a traditional vehicle or placebo arm, may be sufficient for U.S. marketing approval, and that it remains on track to complete Phase 3 recruitment by the end of 2026 with a potential NDA filing in 2027. Quoin also advanced its QRX009 topical rapamycin platform with planned investigator-led studies in multiple rare dermatologic indications and an IND filing targeted for Q3 2026, while reporting a cash balance of approximately $14 million as of March 31, 2026, which it believes will fund operations into 2027, and a quarterly net loss of about $5 million.

Filing Facts

CIK

1671502

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-057140

Alert Tier

7